These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2691221)

  • 41. Different effects of direct and indirect dopamine receptor agonists on immobility time in reserpine-treated mice.
    Zarrindast MR; Minaian A
    Gen Pharmacol; 1991; 22(6):1017-21. PubMed ID: 1687391
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dopaminergic mechanisms and motor function: characterization of D-1 and D-2 dopamine receptor interactions.
    Barone P; Davis TA; Braun AR; Chase TN
    Eur J Pharmacol; 1986 Apr; 123(1):109-14. PubMed ID: 2872071
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of dopamine receptor involvement in rat feeding behaviour.
    Zarrindast MR; Owji AA; Hosseini-Nia T
    Gen Pharmacol; 1991; 22(6):1011-6. PubMed ID: 1687390
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Absence of D1 dopamine receptors that stimulate prolactin release in the rat pituitary.
    Cocchi D; Ingrassia S; Rusconi L; Villa I; Müller EE
    Eur J Pharmacol; 1987 Oct; 142(3):425-9. PubMed ID: 2962879
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Behavioral and biochemical expression of D1-receptor supersensitivity following SCH 23390 repeated administrations.
    Gandolfi O; Roncada P; Dall'Olio R; Montanaro N
    Brain Res; 1988 Jul; 455(2):390-3. PubMed ID: 2969768
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Climbing and stereotyped behaviours in mice require the stimulation of D-1 dopamine receptors.
    Vasse M; Chagraoui A; Protais P
    Eur J Pharmacol; 1988 Mar; 148(2):221-9. PubMed ID: 2897924
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Differential effects of dopamine agonists on locomotion in intact and reserpine-treated mice.
    Zarrindast MR; Eliassi A
    Gen Pharmacol; 1991; 22(6):1027-31. PubMed ID: 1687393
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of dopaminergic agonists and antagonists on the serum prolactin levels in alcoholized rats.
    Samochowiec J; Kleinrok Z; Jagiełło-Wójtowicz E; Horodnicki J; Rommelspacher H; Schmidt LG
    Pol J Pharmacol; 1997 Aug; 49(4):221-7. PubMed ID: 9437765
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dopamine receptor subtypes: in vivo biochemical evidence for functional interaction.
    Saller CF; Salama AI
    Eur J Pharmacol; 1985 Feb; 109(2):297-300. PubMed ID: 3873343
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Supersensitivity to a D-1 dopamine receptor agonist and subsensitivity to a D-2 receptor agonist following chronic D-1 receptor blockade.
    Barone P; Tucci I; Parashos SA; Chase TN
    Eur J Pharmacol; 1988 May; 149(3):225-32. PubMed ID: 3261693
    [TBL] [Abstract][Full Text] [Related]  

  • 51. D-1 type of dopamine autoreceptors are not involved in the regulation of dopamine synthesis in the striatum.
    Watanabe H; Suda H; Sekihara S; Nomura Y
    Jpn J Pharmacol; 1987 Mar; 43(3):327-30. PubMed ID: 3495683
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of the D1 receptor agonist SKF 38393 on some behavioural effects of apomorphine in rats.
    Zarkovsky AM; Cereska KS
    Naunyn Schmiedebergs Arch Pharmacol; 1989 Apr; 339(4):383-6. PubMed ID: 2567965
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Permissive role of D-1 receptor stimulation for the expression of D-2 mediated behavioral responses: a quantitative phenomenological study in rats.
    Longoni R; Spina L; Di Chiara G
    Life Sci; 1987 Nov; 41(18):2135-45. PubMed ID: 2959833
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Modulation of dopaminergic terminal excitability by D1 selective agents.
    Diana M; Young SJ; Groves PM
    Neuropharmacology; 1989 Jan; 28(1):99-101. PubMed ID: 2522599
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Opposite effects of stimulation of D1 and D2 dopamine receptors on the expression of motor seizures in mouse and rat.
    al-Tajir G; Chandler CJ; Starr BS; Starr MS
    Neuropharmacology; 1990 Jul; 29(7):657-61. PubMed ID: 1974713
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A D2 dopamine receptor agonist disrupts sensorimotor gating in rats. Implications for dopaminergic abnormalities in schizophrenia.
    Peng RY; Mansbach RS; Braff DL; Geyer MA
    Neuropsychopharmacology; 1990 Jun; 3(3):211-8. PubMed ID: 2141986
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bromocriptine induces marked locomotor stimulation in dopamine-depleted mice when D-1 dopamine receptors are stimulated with SKF38393.
    Jackson DM; Hashizume M
    Psychopharmacology (Berl); 1986; 90(1):147-9. PubMed ID: 3094056
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role of genotype and dopamine receptors in behaviour of inbred mice in a forced swimming test.
    Nikulina EM; Skrinskaya JA; Popova NK
    Psychopharmacology (Berl); 1991; 105(4):525-9. PubMed ID: 1685251
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Interactions of D1 and D2 dopamine receptors on the ipsilateral vs. contralateral side in rats with unilateral lesions of the dopaminergic nigrostriatal pathway.
    Sonsalla PK; Manzino L; Heikkila RE
    J Pharmacol Exp Ther; 1988 Oct; 247(1):180-5. PubMed ID: 2971797
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The discriminative stimulus properties of the D-1 agonist SK&F 38393 and the D-2 agonist (-)-NPA are mediated by separate mechanisms.
    Arnt J
    Life Sci; 1988; 42(5):565-74. PubMed ID: 2963185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.